American Association for Cancer Research
- The editors are publishing this note to alert readers to a concern about this article (1). In Fig. 7A, the images representing p-EGFRY1173, TRIM59, and p-STAT3Y705 in sample 2 were subsections of the same image and included overlapping regions. The authors located original data from a separate GBM specimen collected on the same day, which […]
- AbstractBacillus Calmette–Guérin (BCG) is the current standard of care for non–muscle-invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating unresponsive patients. Stimulator of IFN genes (STING) plays a central role in mounting innate and adaptive immune responses to tumor cells, and activation of STING is […]
- In the original version of this article (1), author Laura D. Wood is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.
- AbstractCancer genomics consortia have identified somatic drivers of breast cancer subtypes. However, these studies have predominantly included older, non-Black women, and the related socioeconomic status (SES) data are limited. Increased representation and depth of social data are crucial for understanding how health inequity is intertwined with somatic landscapes. Here, we conducted targeted sequencing on primary […]
- AbstractDNA methyltransferase (DNMT) and PARP inhibitors induce a stimulator of IFN gene–dependent pathogen mimicry response (PMR) in ovarian and other cancers. In this study, we showed that combining DNMT and PARP inhibitors upregulates expression of the nucleic acid sensor NFX1-type zinc finger–containing 1 (ZNFX1) protein. ZNFX1 mediated the induction of PMR in mitochondria, serving as […]
- AbstractHypoxia is a common feature of solid tumors and is associated with a poor response to anticancer therapies. Hypoxia also induces metabolic changes, such as a switch to glycolysis. This glycolytic switch causes acidification of the tumor microenvironment (TME), thereby attenuating the anticancer immune response. A promising therapeutic strategy to reduce hypoxia and thereby sensitize […]
- SummaryLINE-1 retrotransposons, comprising 17% of the genome, drive cancer instability through hypomethylation. The Detection of long Interspersed nuclear element Altered Methylation ON plasma DNA (DIAMOND) assay, targeting LINE-1 hypomethylation with bisulfite sequencing of cell-free DNA, achieved AUCs of 88% to 100% across six cancer types, surpassing mutation-based diagnostics and suggesting utility in early cancer detection […]
- AbstractPurpose:We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS).Patients and Methods:Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every […]
- AbstractPurpose:Data on clear-cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of hypoxia-inducible factor-1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib […]
- AbstractPurpose:Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown.Experimental Design:We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn […]
Cancer.gov
- A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.
- A study of 85,000 older adults in the U.K. suggests that light- and moderate-to-vigorous-intensity daily physical activity can reduce cancer risk. The number of steps taken daily may be more important for cancer risk than the intensity of activity, the study shows.
- An NCI clinical trial showed that an experimental gene therapy called PRGN-2012 may be an effective treatment for recurrent respiratory papillomatosis, which is caused by HPV 6 and HPV 11.
- Over the past 45 years, the majority of deaths averted from breast, cervical, colorectal, lung, and prostate cancer were due to prevention and screening, rather than treatment advances, NCI researchers have found.
- A new study led by NCI researchers shows that mutant RAS proteins help release a nuclear protein from a complex transported from the nucleus to the cytoplasm, kicking off a series of events that lead to the breakdown of a tumor suppressor protein.
JAMA Oncology – Current Issue
- The Original Investigation titled “Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX,” published online January 23, 2025, contained an error in the Results section. The correct 5-year overall survival for patients who received adjuvant (m)FOLFIRINOX (a combination of leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) […]
- This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with nivolumab plus brentuximab vedotin followed by brentuximab vedotin plus bendamustine for patients with suboptimal response and involved-site radiotherapy.
- This Review describes why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of central nervous system tumors.
- This randomized clinical trial evaluates the efficacy of sharing follow-up care between the specialty center and a local oncology practice after allogeneic hematopoietic cell transplantation.
- Current up-front therapeutic approaches for classic Hodgkin lymphoma (cHL) in children and young adults aim to reduce treatment intensity to minimize long-term treatment-related morbidity. This strategy assumes that patients who relapse can still achieve durable remission with a combination of high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT). Although this goal is achievable for […]
ClinicalTrials.gov – Cancer
- Conditions: Cholangiocarcinoma; Colorectal Cancer; Multiple Myeloma Interventions: Other: Standard developed materials; Other: Genetics Advisor Decision Aid Sponsors: Washington University School of Medicine; National Cancer Institute (NCI) Recruiting
- Conditions: Colorectal Cancer; Breast Cancer; Non Metastatic Cancer Interventions: Other: Exercise Sponsors: Université de Sherbrooke Recruiting
- Conditions: Liver Transplantation in Locally Advanced Intrahepatic Cholangiocarcinoma Interventions: Procedure: Liver transplant Sponsors: Assistance Publique – Hôpitaux de Paris Not yet recruiting
- Conditions: Malignant Pleural Mesothelioma Interventions: Radiation: hemithoracic Volumetric Arc Radiotherapy post Pleural decortication Sponsors: Cairo University Recruiting
- Conditions: B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors Interventions: Biological: MT027 CAR-T cells Sponsors: Zhejiang University Recruiting
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email [email protected]